The Vanguard Group, Inc. recently announced the acquisition of new stake in TScan Therapeutics Inc. (NASDAQ:TCRX). The institutional investor has increased its shareholding in the Healthcare company by 13.93% to 0.26 million shares with purchase of 31356.0 shares. This fresh investment now brings its stake to 1.35% valued currently at $0.4 million. In addition, Geode Capital Management LLC raised its holdings by 66568.0 to 0.1 million shares.
With over 6.07 million TScan Therapeutics Inc. (TCRX) shares trading Monday and a closing price of $2.08 on the day, the dollar volume was approximately $12.62 million. The shares have shown a negative half year performance of -37.91% and its price on 01/23/23 lost nearly -0.95%. Currently, there are 24.07M common shares owned by the public and among those 17.61M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for TCRX have a consensus price objective of $14.00. The analysts have set the share’s price value over the next 12 months at a high of $21.00 and a low of $6.00. The average price target is 85.14% above its recent price level and an upside to the estimated low will see the stock gain 65.33% over that period. But an upside of 90.1% will see the stock hit the forecast high price target while median target price for the stock is $14.50.
Insiders at the company have transacted a total of 13 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 13 of these insider trades were purchases, accounting for 1,405,792 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in TScan Therapeutics Inc. are BlackRock Health Sciences Trust I, BlackRock Health Sciences Opportu, and Vanguard Total Stock Market Index. BlackRock Health Sciences Trust I owns 0.86 million shares of the company’s stock, all valued at over $1.33 million. Vanguard Total Stock Market Index now owns shares totaling to 1.17% of the shares outstanding.
Shares of TScan Therapeutics Inc. (NASDAQ: TCRX) opened at $2.54, up $0.44 from a prior closing price of $2.10. However, the script later moved the day high at 2.6700, down -0.95%. The company’s stock has a 5-day price change of -5.45% and -35.00% over the past three months. TCRX shares are trading 34.19% year to date (YTD), with the 12-month market performance down to -55.93% lower. It has a 12-month low price of $1.45 and touched a high of $5.60 over the same period. TCRX has an average intraday trading volume of 26.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.14%, 0.75%, and -24.78% respectively.
Institutional ownership of TScan Therapeutics Inc. (NASDAQ: TCRX) shares accounts for 63.50% of the company’s 24.07M shares outstanding. Mutual fund holders own 16.26%, while other institutional holders and individual stakeholders account for 26.19% and 12.09% respectively.
It has a market capitalization of $49.63M. The earnings-per-share (ttm) stands at -$2.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.18% over the week and 17.09% over the month.
Analysts forecast that TScan Therapeutics Inc. (TCRX) will achieve an EPS of -$0.72 for the current quarter, -$0.73 for the next quarter and -$2.85 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.8 while analysts give the company a high EPS estimate of -$0.65. Comparatively, EPS for the current quarter was -$0.8 a year ago. Earnings per share for the fiscal year are expected to decrease by -86.10%, and -10.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate TScan Therapeutics Inc. (TCRX) as a “Strong Buy” at a consensus score of 1.80. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
